1
H NMR spectrum of a reaction mixture of thymidine monophosphate (TMP) and HCHO in D2O at pD 7. 
EXPERIMENTAL Materials
Adenosine, adenosine monophosphate, adenosine diphosphate, adenosine triphosphate, deoxyadenosine monophosphate, cytidine, deoxycytidine, deoxycytidine monophosphate, deoxyguanosine monophosphate, thymidine monophosphate, (5-hydroxymethyl)deoxycytidine,
(1-methyl)adenosine, (6-methyl)adenosine, (5-methyl)deoxycytidine, and uridine monophosphate were from Sigma Aldrich. Recombinant FTO protein was produced in Escherichia coli as reported.
1 Procedures for the synthesis of m6A phosphoramidite, (6) (7) (8) (9) (10) (11) (12) (13) C-methyl)adenosine and (3-13 C-methyl) thymidine, used in the experiments with FTO, are given in the Supplementary Information. Ammonium formate buffer was prepared as reported. 2 All other reagents were from Sigma Aldrich.
NMR Experiments
NMR experiments were carried out using either a Bruker AVII 500 spectrometer equipped with a TXI probe, a Bruker AVIII 600 spectrometer equipped with a Prodigy N2 broadband cryoprobe, or a Bruker AVIII 700 spectrometer equipped with an inverse TCI Figure S4 (2-25-fold dilutions) were carried out by pre-incubating stock solutions of nucleotides (10 mM) and HCHO (8 equivalents) for one week, before splitting the stock solutions and diluting with the appropriate quantities of D2O.
EXSY analyses were carried out using a 1-dimensional gradient-selected NOESY pulse sequence employing selective refocusing with a Gaussian pulse. [3] [4] [5] Experiments were run accumulating 16 transients with mixing times (τm) of 10-1200 ms, with the 1 H-resonance of hydrated HCHO (δH 4.89 ppm at 37 °C) being selectively irradiated. Adduct formation rates were calculated as follows: the normalised intensities of the EXSY correlations (i.e. the intensities of the 1 H-resonances corresponding to the adduct N-hydroxymethyl protons normalised to the intensity of the irradiated HCHO resonance) were plotted as a function of τm, and the initial intensity build-up rates were determined (see Figure S11) . Assuming a bimolecular mechanism for adduct formation, the build-up rates represent k1 [nucleotideeq] , where k1 is the rate constant for adduct formation, and [nucleotideeq] is the concentration of unreacted nucleotide at equilibrium (see below). The initial adduct formation rate for 3hmUMP and 3hmTMP were calculated by dividing their accumulation rate by [nucleotideeq] , with a final concentration of 20 µM), the nucleoside selectively 13 C-labelled of the methyl group (400 µM), 2-oxoglutarate (2OG, 5 mM), sodium ascorbate (1 mM), ferrous iron (20 µM) in ammonium formate buffer in D2O pH* 7.5. The samples were then transferred to 3 mM MATCH NMR tubes (Hilgenberg) and monitored by NMR. 
MS-Based FTO Activity Assay
A reaction mixture containing RNA oligonucleotide (AUUGUGG-m6A-CUGCAGC, 1 µM), 2OG (10 µM), ascorbate (100 µM), ferrous iron (10 µM) and FTO (100 nM) in 50 mM Tris buffer in H2O at pH 7.5 was prepared in a 2 mL 96-well plate (Greiner) and reaction progression was monitored by MS using an Agilent RapidFire RF360 high throughput system paired with an Agilent quad time of flight (Q-TOF) mass spectrometer. Aliquots from the mixture were periodically subjected to MS analysis (at 1 minute intervals over the first 14 minutes after mixing, then at 23 minutes and 33 minute after mixing). The sample was passed through an Agilent C8 RapidFire cartridge, which isolated the oligonucleotides; the oligonucleotides were then eluted from the cartridge with 600mM octyl ammonium acetate (OAA) (20 %) and acetonitrile (80 %), and injected into the spectrometer. The RapidFire RF360 system was operated using RapidFire RF360 integrated software, and the mass spectrometer was operated using Agilent MassHunter Workstation Data Acquisition software. Signal intensities were quantified as the total ion count, and analysed using RapidFire integrator software (Agilent). Detailed RapidFire-MS procedures will be published elsewhere.
CHEMICAL SYNTHESIS

General Methods
All chemicals, including dried solvents, were from Sigma-Aldrich and used without further purification. Solvents used for work-up and chromatography were from Aldrich at HPLC grade. Silica gel 60 F254 analytical thin layer chromatography (TLC) plates were from Merck. Prepacked SNAP columns were used for chromatography on a Biotage SP1 Purification system. Proton and Carbon NMR spectra were acquired using AVIIIHD 500 or Bruker AVIIIHD 400 or AVIIIHD 600 with N2 cryoprobe. Shifts are reported in δ ppm. 
3', 5'-O-Bis(t-butyldimethylsilyl)thymidine
This compound was synthesised using a reported procedure. 7 To a stirred solution of 2'-deoxythymidine (2 g, 8.3 mmol) and imidazole (2.25 g, 33.026 mmol) in dry DMF in a 50 mL round bottom flask was added TBDMSCl (2.74 g, 18.16 mmol) portionwise. The reaction was stirred for four hours. The resulting mixture was concentrated under reduced pressure, then diluted with EtOAc. The EtOAc layer was washed with water (3 x 10 mL), and finally with brine. The organic layer was dried over MgSO4 and concentrated in vacuo. Mixture was purified (19:1 to 4:1 cyclohexane / EtOAc) by column chromatography which resulted in an off-white solid (3.3 g, 86%) . m.p.: 150.8 °C.TLC Rf 0.15 (4:1 cyclohexane / EtOAc). 
3', 5'-O-Bis(t-butyldimethylsilyl)-N3-(
C)methylthymidine
3', 5'-O-Bis(t-butyldimethylsilyl)-2'-deoxythymidine (0.8 g, 1.7 mmol) was dissolved in anhydrous DMF at 0°C under a nitrogen atmosphere. NaH (0.072 g, 1.78 mmol) was dissolved in DMF; this solution was carefully added and the resultant mixture was stirred for 1 hr to give a clear solution. This compound was prepared according to a modified version of a reported procedure. 8 To a stirred solution of 3', 5'-O-Bis(t-butyldimethylsilyl)-N3-( 
3',5'-O-Bis(t-butylsilyl)-2'-O-(t-butyldimethylsilyl)adenosine
This compound was prepared according to a modified version of a reported procedure. 9 To a stirred suspension of adenosine (2.12 g, 8 mmol) in 40 mL anhydrous DMF at 0 °C, di-tbutylsilyl ditrifluoromethanesulfonate (3.87 mL, 8.8 mmol) was added drop wise under an N2 atmosphere. After consumption of starting material (30 min, as assessed by TLC), the reaction was quenched immediately with imidazole (2.7 g, 40 mmol) at 0 °C. After 5 minutes, the reaction was warmed to room temperature. Then, t-butyldimethylsilyl chloride (1.45 g, 9.6 mmol) was added portion wise and the reaction was refluxed at 60 °C for 12 hr. The suspension was cooled down to room temperature, water was added and the precipitate was collected by suction filtration. The filtrate was discarded, and the white precipitate was washed with cold MeOH. The MeOH layer was evaporated under reduced pressure and the product was crystallised from CH2Cl2 to give a white solid (3. 
3',5'-O-Bis(t-butylsilyl)-2'-O-(t-butyldimethylsilyl)-N6-benzoyladenosine
This compound was prepared according to a modified version of a reported procedure. 9 To a stirred solution of 3',5'-O-bis(t-butylsilyl)-2'-O-(t-butyldimethylsilyl)adenosine (2.08 g, 4 mmol) in 10 mL anhydrous pyridine at -5 °C (salt-ice bath), benzoyl chloride (0.93 mL, 8 mmol,) was added drop wise. The reaction mixture was allowed to warm to room temperature for 1 hour, and stirred further for 18 hours under N2. The reaction was quenched first with 6 mL MeOH at 0 °C and then with excess methanolic ammonia (1 mL, 7 N NH3) after 1 hr. The crude product mixture was concentrated under pressure, and was then diluted with EtOAc and saturated NaHCO3 solution. The organic layer was washed with water (3 x 10 mL) and dried with anhydrous MgSO4 and reduced under vacuum. The mixture was purified (6:1 to 3:1 cyclohexane / EtOAc) by column chromatography resulting in an off-white solid (2.2 g, 88%). mp 127-128 °C TLC Rf 0.35 (2:3 cyclohexane / EtOAc). 
3',5'-O-Bis(t-butylsilyl)-2'-O-(t-butyldimethylsilyl)-N6,N6-benzoyl-(
C)-methyladenosine
The compound was prepared according to a modified reported procedure. 10 To a solution of 3',5'-O-bis(t-butylsilyl)-2'-O-(t-butyldimethylsilyl)-N6-benzoyladenosine (260 mg, 0.42 mmol) in 5 mL CH2Cl2, tetrabutylammonium bromide (0.23 g, 1.6 mmol) and 1 N aq. NaOH (excess) were added. After 20 min, 13 C-methyl iodide (104 µL, 1.7 mmol) was added to the reaction mixture and further stirred for 24 hr. Excess CH2Cl2 was added and the mixture was washed with water (3 x 10 mL). The organic phase was then dried (MgSO4) and concentrated under reduced pressure. The residue was purified by column chromatography (4:1 to 3:2 cyclohexane / EtOAc) which resulted in an oil (140 mg, 52 %). TLC Rf 0.5 (7:3 cyclohexane / EtOAc). CDCl3) δ -5.0, -4.3, 18.3, 20.4, 22.8, 25.9, 27.0, 27.5, 35.9, 36.9, 67.8, 74.7,  75.8, 75.9, 91.9, 122.7, 128.1, 129.8, 132.0, 135.7, 137.7, 144.7, 146.0, 146.9 
3',5'-O-Bis(t-butylsilyl)-2'-O-(t-butyldimethylsilyl)-N6-(
C)methyladenosine
This compound was prepared according to a modified version of a reported procedure. 11 To a stirred solution of 3',5'-O-bis(t-butylsilyl)-2'-O-(t-butyldimethylsilyl)-N6,N6-benzoyl-( 13 C)-methyladenosine (140 mg, 0.22 mmol) in THF (2 ml) at 0 °C, lithium triethylborohydride (1 M in THF, 1.1 mL, 1.09 mmol) was added and stirred for 1 hr at room temperature. The reaction was quenched by addition of saturated aqueous NH4Cl, followed by 1 N NaOH. The crude product mixture was concentrated under vacuum, then diluted with EtOAc, then washed with water (3 x 10 mL). The organic layer was dried (MgSO4) and concentrated under reduced pressure. The residue was purified by column chromatography (9:1 to 3:2 cyclohexane / EtOAc) which resulted in an oil (88 mg, 75%). TLC Rf 0.2 (7:3 cyclohexane / EtOAc). 
3',5'-O-Bis(t-butylsilyl)-2'-O-(t-butyldimethylsilyl)-N6,N6-benzoylmethyladenosine
The compound was prepared according to a version of a reported procedure. 10 To a solution of 3',5'-O-Bis(tert-butylsilyl)-2'-O-(tert-butyldimethylsilyl)-N 6 -benzoyladenosine (1 g, 1.6 mmol) in 5 mL CH2Cl2, tetra-butylammonium bromide (0.88 g, 2.4 mmol) and 1 N aq. NaOH (excess) were added. After 20 min, methyl iodide (0.4 mL, 6.4 mmol) was added to the reaction mixture and further stirred for 24 hr. Excess CH2Cl2 was added to the residue and washed with water (3x10ml). The organic phase was dried (MgSO4) and concentrated under vacuum. The residue was purified by column chromatography (4:1 to 3:2 cyclohexane / EtOAc) to give an oil (663 mg, 65%). TLC Rf 0.5 (7:3 C6H12 /EtOAc); 
5'-O-(4,4'-Dimethoxytrityl)-2'-O-dimethyl(tert-butyl)silyl-N6-methyladenosine
This compound was prepared according to a reported procedure. 12 To a stirred solution of 2'-O-dimethyl(tert-butyl)silyl-N6-methyladenosine (2.6 g, 6.4 mmol) in 4 mL anhydrous pyridine at 0°C, DMTrCl (2.5 g, 7.6 mmol) was added portion wise at regular intervals for 12 hr. The reaction was quenched by addition of an excess of anhydrous MeOH (0.5 mL) at room temperature. After 1 hr, the solution was concentrated under vacuum. The crude solid was first fractioned between aqueous NaHCO3 and EtOAc, and then the organic layer was washed with water (3 x 10 mL). The organic layer dried MgSO4 and concentrated under vacuum. The residue was purified by column chromatography (9:1 to 3:2 cyclohexane / EtOAc) to give a yellow oil ( 
Synthesis of (6-methyl)guanosine
Scheme S3. Route to (6-methyl)guanosine. i) imidazole, TBDMSCl, DMF; ii) BOP, CsCO3, MeOH; iii) 3HF.NEt3, CH2Cl2.
2', 3', 5'-O-tri(t-Butyldimethylsilyl)guanosine
This compound was synthesized using a reported procedure. 13 To a stirred solution of guanosine (2 g, 8.3 mmol) and imidazole (3.75 g, 13.24 mmol) in dry DMF in a 50 mL round bottom flask was added TBDMSCl (6.58 g, 43.69 mmol) portion-wise. The reaction was stirred overnight. The resulting mixture was concentrated under reduced pressure and was diluted with EtOAc. The EtOAc layer was washed with water (3 x 10 mL) and finally with brine. The organic layer was dried over MgSO4 and concentrated under reduced pressure. The mixture was purified (19:1 to 4:1 cyclohexane / EtOAc) by column chromatography resulting in an offwhite solid (7.0 g, 84.5 %). TLC Rf 0.6 (9:1 CH2Cl2 / MeOH) m.p: 193.5°C. 
